Faithward Advisors’s Biogen BIIB Stock Holding History

Faithward Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-739	Closed	-$234K	–	214
2020 Q1	$234K	Buy	739 +59	+9%	+$17.9K	0.07%	142
2019 Q4	$202K	Buy	+680	New	+$189K	0.05%	152

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Faithward Advisors's BIIB Position: Q2 2020 in Review

Faithward Advisors sold out of Biogen (BIIB) in Q2 2020, closing a stake of 739 shares — an estimated $234K sold.

Faithward Advisors first reported a position in BIIB in Q4 2019 and held it in 2 quarters. The position peaked at $234K in Q1 2020. 1,060 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

Faithward Advisors reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
Faithward Advisors sold 739 Biogen shares in Q2 2020, an estimated $234K.
Faithward Advisors first reported a position in Biogen in Q4 2019 and held it in 2 quarters.
Faithward Advisors's Biogen position peaked at $234K in Q1 2020.
1,060 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Faithward Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.